In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: Distinct patterns in the different clinical phenotypes

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Balduini, Alessandra ^a,b   Badalucco, Stefania ^a   Pugliano, Maria Teresa ^c   Baev, Denis ^d   de Silvestri, Annalisa ^e   Cattaneo, Marco ^c   Rosti, Vittorio ^e   Barosi, Giovanni ^e  

^a UNIVERSITY OF PAVIA   (Italy)

^b Tufts University   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d ViroStatics Srl   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD45 ANTIGEN;

ADULT; ARTICLE; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; JAK2 GENE; MALE; MEGAKARYOCYTE; MYELOID METAPLASIA; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYCYTHEMIA VERA; PROPLATELET; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTHEMIA; CASE CONTROL STUDY; CYTOLOGY; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; MUTATION; MYELOPROLIFERATIVE DISORDER; PATHOLOGY; PHILADELPHIA 1 CHROMOSOME;

BLOOD PLATELETS; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; HUMANS; IMMUNOPHENOTYPING; MEGAKARYOCYTES; MUTATION; MYELOPROLIFERATIVE DISORDERS; PHILADELPHIA CHROMOSOME;

EID: 79959254853     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021015     Document Type: Article

References (42)

1. Kaushansky K, (2005) The molecular mechanisms that control thrombopoiesis. J Clin Invest 115 (12): 3339-3347.
2. Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, et al. (2004) Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 10 (1): 64-71.
3. Hartwig J, Italiano J Jr, (2003) The birth of the platelet. J Thromb Haemost 1 (7): 1580-1586.
4. Patel SR, Hartwig JH, Italiano JE Jr, (2005) The biogenesis of platelets from megakaryocyte proplatelets. J Clin Invest 115 (12): 3348-3354.
5. Schulze H, Shivdasani RA, (2005) Mechanisms of thrombopoiesis. J Thromb Haemost 3 (8): 1717-1724.
6. Italiano JE Jr, Shivdasani RA, (2003) Megakaryocytes and beyond: the birth of platelets. J Thromb Haemost 1 (6): 1174-1182.
7. Becker RP, De Bruyn PP, (1976) The transmural passage of blood cells into myeloid sinusoids and the entry of platelets into the sinusoidal circulation; a scanning electron microscopic investigation. Am J Anat 145 (2): 183-205.
8. Junt T, Schulze H, Chen Z, Massberg S, Goerge T, et al. (2007) Dynamic visualization of thrombopoiesis within bone marrow. Science 317 (5845): 1767-1770.
9. Thon JN, Montalvo A, Patel-Hett S, Devine MT, Richardson JL, et al. (2010) Cytoskeletal mechanics of proplatelet maturation and platelet release. J Cell Biol 191 (4): 861-874.
10. Barosi G, Hoffman R, (2005) Idiopathic myelofibrosis. Semin Hematol 42 (4): 248-258.
11. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al. (2008) WHO classification of tumors of haematopoietic and lymphoid tissues Lyon IARC.
12. Ciurea SO, Merchant D, Mahmud N, Ishii T, Zhao Y, et al. (2007) Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood 110 (3): 986-993.
13. Muth M, Busche G, Bock O, Hussein K, Kreipe H, (2010) Aberrant proplatelet formation in chronic myeloproliferative neoplasms. Leuk Res 34 (11): 1424-1429.
14. Haylock DN, To LB, Dowse TL, Juttner CA, Simmons PJ, (1992) Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. Blood 15;80 (6): 1405-12.
15. Weisdorf DJ, Verfaille CM, Miller WJ, Blazar BR, Perry E, et al. (1997) Autologous bone marrow versus non-mobilized peripheral blood stem cell transplantation for lymphoid malignancies: a prospective, comparative trial. Am J Hematol 54 (3): 202-8.
16. Chang Q, Harvey K, Akard L, Thompson J, Dugan MJ, et al. (1997) Differences in CD34+ cell subpopulations between human bone marrow and "mobilized" peripheral blood as determined with counterflow centrifugal elutriation. Exp Hematol 25 (5): 423-31.
17. Williams N, Levine RF, (1982) The origin, development and regulation of megakaryocytes. Br J Haematol 52 (2): 173-180.
18. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (9464): 1054-1061.
19. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, et al. (2009) A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 41 (4): 455-459.
20. Levine RL, Wernig G, (2006) Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. Hematology Am Soc Hematol Educ Program pp. 233-239, 510.
21. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (7037): 1144-1148.
22. Li J, Spensberger D, Ahn JS, Anand S, Beer PA, et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 116 (9): 1528-1538.
23. Taksin AL, Couedic JP, Dusanter-Fourt I, Masse A, Giraudier S, et al. (1999) Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood 93 (1): 125-139.
24. Barosi G, (1999) Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 17 (9): 2954-2970.
25. Boveri E, Passamonti F, Rumi E, Pietra D, Elena C, et al. (2008) Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. Br J Haematol 140 (2): 162-168.
26. Thiele J, Holgado S, Choritz H, Georgii A, (1982) Abnormalities of megakaryocytes in myelitis and chronic myeloproliferative diseases. Virchows Arch B Cell Pathol Incl Mol Pathol 41 (1-2): 67-81.
27. Besancenot R, Chaligne R, Tonetti C, Pasquier F, Marty C, et al. A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation. PLoS Biol 8 (9).
28. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, et al. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114 (5): 937-951.
29. Thiele J, Pierre R, Imbert M, (2001) Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris N, Stan H, Vardiman JW, editors. World Health Organization of Tumors of Hematopoietic and Lymphoid Tissues Washington DC IARC Press pp. 35-38.
30. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, et al. (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90 (8): 1128-1132.
31. Balduini A, Pallotta I, Malara A, Lova P, Pecci A, et al. (2008) Adhesive receptors, extracellular proteins and myosin IIA orchestrate proplatelet formation by human megakaryocytes. J Thromb Haemost 6 (11): 1900-1907.
32. Larson MK, Watson SP, (2006) Regulation of proplatelet formation and platelet release by integrin alpha IIb beta3. Blood 108 (5): 1509-1514.
33. Lataillade JJ, Pierre-Louis O, Hasselbalch HC, Uzan G, Jasmin C, et al. (2008) Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood 112 (8): 3026-3035.
34. Giraudier S, Chagraoui H, Komura E, Barnache S, Blanchet B, et al. (2002) Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors. Blood 100 (8): 2932-2940.
35. Tefferi A, Gangat N, Wolanskyj AP, (2006) Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter? Blood 108 (7): 2493-2494.
36. Kaushansky K, (2006) Hematopoietic growth factors, signaling and the chronic myeloproliferative disorders. Cytokine Growth Factor Rev 17 (6): 423-430.
37. Vannucchi AM, Bianchi L, Paoletti F, Pancrazzi A, Torre E, et al. (2005) A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. Blood 105 (9): 3493-3501.
38. Chaligne R, Tonetti C, Besancenot R, Marty C, Kiladjian JJ, et al. (2009) SOCS3 inhibits TPO-stimulated, but not spontaneous, megakaryocytic growth in primary myelofibrosis. Leukemia 23 (6): 1186-1190.
39. Hoffman R, Prchal JT, Samuelson S, Ciurea SO, Rondelli D, (2007) Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment. Biol Blood Marrow Transplant 13 (1 Suppl 1): 64-72.
40. Barosi G, Viarengo G, Pecci A, Rosti V, Piaggio G, et al. (2001) Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 98 (12): 3249-3255.
41. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061.
42. Balduini A, Malara A, Pecci A, Badalucco S, Bozzi V, et al. (2009) Proplatelet formation in heterozygous Bernard-Soulier syndrome type Bolzano. J Thromb Haemost 7 (3): 478-484.